-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Group has been ranked among the top 10 in the 2023 China Chemical Drug R&D Strength Ranking.
Category:
Time：2023-06-16
Gathering talents from all over to drive industrial development. On June 16, the 2023 High-Quality Development Conference for the Greater Health Industry and the 8th China Pharmaceutical R&D & Innovation Summit, jointly hosted by Yaozhi.com and the magazine China Pharmaceutical Industry, were held in Chongqing, the "Mountain City." At the opening ceremony of this summit, the highly anticipated 2023 Ranking Series of China’s Pharmaceutical R&D Strength was officially unveiled. Shijiazhuang Fourth Pharmaceutical Group was listed among the Top 30 in the 2023 China Pharmaceutical R&D Comprehensive Strength Ranking and among the Top 10 in the 2023 China Chemical Pharmaceutical R&D Strength Ranking. Qu Jiguang, Chairman of the Group’s Board of Directors, was honored with the prestigious title of 2023 China Pharmaceutical Innovation Leader.
Gathering top talents from all over to drive industrial development. On June 16, the 2023 High-Quality Development Conference for the Greater Health Industry and the 8th China Pharmaceutical R&D & Innovation Summit—jointly hosted by Yaozhi.com and the editorial team of China Pharmaceutical Journal—were held in Chongqing, the "Mountain City." At the opening ceremony of this summit, the highly anticipated 2023 Ranking of China’s Pharmaceutical R&D Strengths was officially unveiled. Shijiazhuang Fourth Pharmaceutical Group was listed among the Top 30 in the 2023 China Pharmaceutical R&D Comprehensive Strength Ranking and among the Top 10 in the 2023 China Chemical Pharmaceutical R&D Strength Ranking. Qu Jiguang, Chairman of the Group’s Board of Directors, was honored with the title of 2023 China’s Leading Figure in Pharmaceutical Innovation.
It is reported that the “2023 China Pharmaceutical R&D Strength Ranking” was compiled by Ya Zhi Net, the Expert Committee for the Pharmaceutical R&D Strength Ranking, and the Organizing Committee of the 2023 China Pharmaceutical R&D Innovation Summit. The ranking is based on a comprehensive statistical analysis of various R&D-related data—including the number of drug applications approved in 2022, the amount of R&D investment by pharmaceutical companies, clinical trials of drugs, patent filings, and historical drug R&D performance—providing a more scientific and objective reflection and evaluation of companies’ overall R&D status and innovation capabilities.
In recent years, Shijiazhuang Sihua Pharmaceutical Group, one of China’s top 100 pharmaceutical companies, has been driven by innovation, closely aligning its efforts with national strategic priorities and market demands. The company has boldly tackled key “bottleneck” technologies, making strategic inroads into fields such as antiviral, antibacterial, anti-tumor, nervous system, cardiovascular, digestive, and anesthetic therapies. It has simultaneously advanced the development and research of generic drugs, innovative new drugs, specialty active pharmaceutical ingredients, pharmaceutical packaging materials, and products that have undergone consistency evaluations. In particular, over the past two years, leveraging a comprehensive package of supportive policies from the national, provincial, and municipal governments, the company has continuously increased its R&D investment. Relying on high-level innovation platforms such as the enterprise technology center recognized by five national agencies and the National-Local Joint Engineering Laboratory, Shijiazhuang Sihua Pharmaceutical Group has teamed up with numerous renowned universities and research institutes—including China Pharmaceutical University, Zhengzhou University, Shenyang Pharmaceutical University, and the Chinese Academy of Medical Sciences—to bring together leading domestic and international pharmaceutical experts and academic leaders. Together, they have established an innovation consortium led by the company, supported by universities and research institutions, and featuring synergistic collaboration among various innovation players. This collaborative ecosystem continually helps the company build new competitive advantages, shape new development patterns, and create fresh opportunities for growth. Since 2022, Shijiazhuang Sihua Pharmaceutical Group has maintained a leading position in China’s industry in terms of the number of approved and filed specialty generic drugs. Currently, the company has nearly 200 projects under development, covering innovative new drugs, high-end complex formulations, and specialty generics. The continuous strengthening of the innovation chain, talent pool, and industrial chain is empowering the company to move steadily toward the mid-to-high end of the value chain, ensuring that it maintains strong momentum for continued growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license